Bulgarian 
Croatian
Czech 
Danish
Dutch
Estonian
Finnish
French
German
Greek
Hungarian
Icelandic
Italian
Latvian
Lithuanian
Maltese
Norwegian
Polish
Portuguese 
Romanian
Slovak
Slovenian
Spanish
SwedishArticle Contents
A.MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer responsible for batch release
Eisai Manufacturing Ltd.
European Knowledge Centre
Mosquito Way
Hatfield, Herts AL10 9SN
United Kingdom
B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
- Kisplyx - Eisai Europe Ltd
- Lenvima - Eisai Europe Ltd
- Fycompa - Eisai Europe Ltd
Prescription drugs listed. Manufacturer: "Eisai Europe Ltd"
C.OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
•Periodic Safety Update Reports
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web- portal.
The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.
D.CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
•Risk Management Plan (RMP)
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
An updated RMP should be submitted:
At the request of the European Medicines Agency;
Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Comments
